Arrowhead’s plozasiran cuts triglycerides up to 81% in late-stage trials, shows promise for severe hypertriglyceridemia

Arrowhead Pharmaceuticals reported positive data from two late-stage studies of its RNA-based drug plozasiran in adults with severe hypertriglyceridemia.

The trials used a subcutaneous injection every three months and achieved median triglyceride reductions of 79% and 81% after one year, compared with about a 27% drop in the placebo groups.

In addition to lipid lowering, the studies tracked acute pancreatitis events, a serious complication linked to very high triglyceride levels, suggesting a potential benefit in reducing such episodes.

Plozasiran is already marketed as Redemplo for a rare genetic disorder that causes extremely high triglycerides, and Arrowhead is now seeking to broaden its indication to treat the more common severe hypertriglyceridemia population.